Cancer Health

 NK Cells: Analysis of Natural Killer Cells in Hematopoietic Stem Cell Transplant Patients and Donors

Natural killer (NK) cells are a type of white blood cell that play an important role in fighting against viral infections. This study collects blood from the donor and the recipient of a hematopoietic stem cell transplant (HSCT) to look at the affect on NK Cells and the ability to fight against a range of viral infections. 

Laura Paulsen 

This study will help us better understand if taking ruxolitinib (the study drug) in combination with corticosteroids is safe and effective in people who have acute graft versus host disease (GVHD) a stem cell transplant.

 

Laura Paulsen 

This is an access study in which umbilical cord blood used for bone marrow transplant is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study. 

Laura Paulsen 

Umbilical cord blood used for bone marrow transplant which is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study.

Laura Paulsen 

This research study will evaluate the ability of umbilical cord blood cells, which have been obtained from multiple unrelated donors, to serve as a source of stem cells for patients undergoing stem cell transplant. The use of a single unrelated umbilical cord blood unit is common for small pediatric patients requiring stem cell transplantation when a related or unrelated donor is not available. For larger patients, the use of more than one umbilical cord blood unit provides an adequate number of stem cells and increases the chances of successful engraftment and survival.

 

Laura Paulsen 

This study is an access protocol to provide treatment of the investigational drug called brincidofovir (BCV) to treat the virus called adenovirus (AdV).

Laura Paulsen

The purpose of this research is to establish an ongoing data collection registry, where a wealth of information provided by patients with gliomas can help future researchers evaluate the practice patterns, as well as pathological and clinical outcomes associated with the treatment of gliomas. 

Eric Laney 

The purpose of this study is to determine the effectiveness of veliparib in the treatment of locally advanced (spread to nearby tissue) or metastatic (spread to other parts of your body) HER 2-negative breast cancer and have been confirmed or highly suspected BRCA1 or BRCA2 mutation.  Secondarily, we will look at how the drug is absorbed, broken down and removed from your body; and look for biomarkers or early signs that the study drug is working. 

Mollie Lockard

The purpose of this study is to compare two standard methods of pain control management used at Spectrum Health for patients undergoing breast surgery. 

The purpose for the study is to learn whether alpelisib, when added to a marketed standard treatment (fulvestrant), helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER 2-negative advanced breast cancer.

Mollie Lockard

616.486.8500

This study is to determine the impact of prostate cancer on a patient’s well-being, study the use of tests and treatment in the care of prostate cancer, and help guide research towards better treatments. 

Sue Engerman

This study is for men who have been on ADT for their recurrent prostate cancer and their PSA continues to rise without evidence of metastasis on imaging. The study drug  is an androgen deprivation therapy that deprives the cancer cells of testosterone needed for cancer growth.

Sue Engerman

616.267.8406 

This study is comparing three standard treatments post removal of a bladder tumor in surgery. Physicians are trying to learn which of these standard treatments provides the chance of preventing tumor recurrence with the least amount of side effects.

Sue Engerman

616.267.8406  

The G-Minor study is for men who have had a radical prostatectomy with high risk factors on their pathology. We  are comparing two tests (the Capra-S Nomogram  and the  Decipher® Test)  to see how they affect the patient and physician's decisions regarding receiving additional treatment after surgery. The tests give a percent chance of the prostate cancer recurring or spreading in the future. 

Sue Engerman

616.267.8406 

This study if for patients who have high grade non-invasive bladder cancer T1, Ta or CIS and whose cancer has recurred despite receipt of BCG therapy. The study drug is an immunotherapy which helps the patients own body to fight the cancer cells. 

Sue Engerman

616.267.8406 

This study will collect biospecimens and medical information for use in laboratory research to learn more about bone tumors and musculoskeletal diseases. Future research is focused on the prevention, diagnosis and treatment. 

Heidi DeVries

616.486.8500

This study is to better understand more about germline mutations (hereditary mutations) in those that have unique circumstances surrounding their medical condition or the medical condition of a family member. Researchers are looking to develop a mechanism for discovery-level genetic research in individuals who have characteristics of a genetic disease or syndrome which cannot currently be linked to a known germline mutation.  Participation is by invitation only.

Heidi DeVries

616.486.8500

This study is being done to look at two different types of surgeries routinely used for treating metastases, the spread of cancer in the upper portion of the femur.

Heidi DeVries

616.486.8500 

Eric Laney 

616.486.8500